Strota/ Newsroom/ 2026-07-19

APLLTD (APLLTD): Regulatory Approval

Strota Newsroom · session of 2026-07-19 · 18 Jul 20:35 · APLLTD stock page →

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "Alembic…

Alembic Pharmaceuticals has informed the exchange that its partner NATCO Pharma received USFDA tentative approval for Olaparib Tablets in 100 mg and 150 mg strengths, according to an NSE filing dated July 18, 2026. The company has reported multiple USFDA approvals in recent weeks, including final approval for Dapsone Gel, 5% on June 26, 2026.

Strota's historical base rate for regulatory approval events shows that stocks with this catalyst type have historically seen positive price momentum in the short term, though outcomes vary significantly by company and market conditions. This pattern reflects how investors typically process new regulatory clearances as potential revenue events, without guaranteeing any specific price movement for this stock.

The company currently trades at a price-to-earnings ratio of 24.04 and price-to-book of 2.86, with a market capitalisation of ₹16,218 crore. Its return on equity stands at 12.4% and the dividend yield is 1.45%. The stock's earnings per share is ₹34.32.

The exchange filing establishes the regulatory approval as a factual event. It does not indicate the commercial launch timeline, revenue contribution, or whether the approval converts from tentative to final status. The data does not establish whether the approval is already reflected in the current valuation or how it compares to previous approvals in the company's pipeline.

The catalyst

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg". (filing · NSE)

What the data shows after this event

Strota has not yet measured a reliable next-session base rate for Regulatory Approval events on enough history.

APLLTD right now

P/E 24.04. Full APLLTD analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.